According to Horizon Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.30767. At the end of 2023 the company had a P/S ratio of 6.45.
Year | P/S ratio | Change |
---|---|---|
2023 | 6.45 | -9.35% |
2022 | 7.12 | -6.05% |
2021 | 7.58 | 3.25% |
2020 | 7.34 | 40.14% |
2019 | 5.24 | 91.61% |
2018 | 2.73 | 20.62% |
2017 | 2.27 | -14.82% |
2016 | 2.66 | -41.82% |
2015 | 4.57 | -15.11% |
2014 | 5.38 | -20.87% |
2013 | 6.80 | -7.11% |
2012 | 7.33 | -35.04% |
2011 | 11.3 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 2.69 | -63.24% | ๐บ๐ธ USA |
Amgen AMGN | 5.41 | -26.03% | ๐บ๐ธ USA |
Merck MRK | 5.56 | -23.93% | ๐บ๐ธ USA |
AstraZeneca AZN | 4.59 | -37.25% | ๐ฌ๐ง UK |
Dr. Reddy's RDY | 3.73 | -48.92% | ๐ฎ๐ณ India |